Specialty Pharma Journal Specialty, Precision & Technology
INGELHEIM, Germany–(BUSINESS WIRE)–Boehringer Ingelheim announced today the first interim results of VARGADO, an ongoing non-interventional study in routine clinical practice in Germany evaluating the efficacy and safety of Vargatef® (nintedanib) and docetaxel in patients with stage III/IV locally advanced or metastatic non-small cell lung cancer (NSCLC) of adenocarcinoma histology. The study …
Tag Archives: Boehringer Ingelheim
December, 2018
November, 2018
-
15 November
Boehringer Ingelheim and Epizyme Partner for Development of Novel Epigenetic Oncology Therapies
CAMBRIDGE, Mass. and INGELHEIM, Germany–(BUSINESS WIRE)–Boehringer Ingelheim and Epizyme, Inc. (Nasdaq: EPZM) today announced a new global collaboration focused on the research, development and commercialization of novel small molecule inhibitors directed toward two previously unaddressed epigenetic targets as potential therapies for people with cancer. Specifically, these targets are enzymes within …
October, 2018
-
19 October
Study Shows using Giotrif/Gilotrif Followed by Osimertinib Provides a Median of 27.6 Months of Chemotherapy-Free Time in Patients with NSCLC
INGELHEIM, Germany–(BUSINESS WIRE)–Boehringer Ingelheim today announced results from GioTag, a real-world retrospective study which examined the impact of first-line Giotrif®/Gilotrif® (afatinib) followed by osimertinib, in epidermal growth factor receptor mutation-positive (EGFR M+) non-small cell lung cancer (NSCLC) patients with acquired T790M mutations, the most common mechanism of resistance to first- and …
September, 2018
-
19 September
Clinical Trial Data for Nintedanib in Patients with Advanced Idiopathic Pulmonary Fibrosis Published
Ingelheim, Germany, 16 September 2018 – Results from the INSTAGE® trial have been presented at the 2018 European Respiratory Society (ERS) conference in Paris and published in the New England Journal of Medicine.1 The trial reports clinical data on a subset of patients with IPF and severe impairment in gas exchange, for whom only …
-
13 September
Boehringer Ingelheim Acquires All Shares of ViraTherapeutics to Develop Next Generation Viral-Based Immuno-Oncology Therapies
INGELHEIM, Germany–(BUSINESS WIRE)–Boehringer Ingelheim today announced that it has acquired all shares of ViraTherapeutics, a biopharmaceutical company specializing in the development of oncolytic viral therapies. ViraTherapeutics developed the lead candidate VSV-GP (Vesicular Stomatitis Virus (VSV) with modified glycoprotein (GP)), which is being investigated alone and in combination with other therapies. …
-
12 September
Biosimilar Cyltezo Demonstrates Clinical Equivalence to Humira in Patients with Moderate-to-Severe Plaque Psoriasis
RIDGEFIELD, Conn., Sept. 12, 2018 /PRNewswire/ — Boehringer Ingelheim today announced results from a phase III study, confirming that Cyltezo® is equivalent to Humira®*, with no clinically meaningful differences in efficacy, safety and immunogenicity in people with moderate-to-severe chronic plaque psoriasis.1 The 16-week data was presented at the European Association …
August, 2018
-
6 August
Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford Biomedica Partner to Develop Gene Therapy for Cystic Fibrosis
INGELHEIM, Germany–(BUSINESS WIRE)–Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium (GTC)—consisting of Imperial College London and the Universities of Oxford and Edinburgh—Imperial Innovations, and Oxford BioMedica (OXB) announce a global collaboration to develop a first-in-class, long-term therapy for patients with cystic fibrosis (CF). The new partnership brings together the …
July, 2018
-
18 July
Boehringer Ingelheim Exercises an Option to License Novel TCR Mimic Antibodies from Eureka Therapeutics
EMERYVILLE, Calif.–(BUSINESS WIRE)–Eureka Therapeutics Inc. announced today that Boehringer Ingelheim has elected to exercise an option for the exclusive license of novel human TCR-mimicking (TCRm) antibodies against an undisclosed target to be used for the potential development and commercialization of therapies for cancer patients. The licensed TCRm antibodies were developed …
-
10 July
Boehringer Ingelheim Acquires Rights to MabVax’s Program Targeting a Glycan Overexpressed in Multiple Solid Tumors
SAN DIEGO, July 9, 2018 /PRNewswire/ — MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage oncology drug development company and Boehringer Ingelheim today announced they have signed an asset acquisition and related agreements centered on MabVax’s program targeting a glycan commonly overexpressed on multiple solid tumor cancers. Boehringer Ingelheim has …
June, 2018
-
25 June
Boehringer Ingelheim and Lilly Announce Top-Line Phase 3 Data Results for Empagliflozin as Adjunct to Insulin in Type 1 Diabetes
INGELHEIM, Germany and INDIANAPOLIS–(BUSINESS WIRE)–Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that both randomized controlled trials in the EASE phase III program, investigating the use of empagliflozin in combination with insulin therapy in adults with type 1 diabetes, met their primary endpoint. The primary efficacy endpoint, …